• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

    10/24/22 9:00:00 AM ET
    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto & Home Supply Stores
    Consumer Discretionary
    Get the next $ELAN alert in real time by email

    TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors.

    Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that eliminate the need of refrigeration for vaccines and therapeutics.

    Ms. Liu serves on the Board of Directors of CarParts.com (NASDAQ:PRTS), a leading online provider of automotive parts and accessories, and served on the Board of Directors of Kindred Biosciences (NASDAQ:KIN), a leading biopharmaceutical company for pets, until it was acquired by Elanco Animal Health (NYSE:ELAN). She serves on the Board of Advisors for Covington Capital Management and is a Partner at XFactor Ventures, a leading investor in women-founded startups. Ms. Liu was named one of Forbes 30 Under 30 (in 2016) and Fortune's 10 Most Promising Women Entrepreneurs (in 2015).

    "For the past 18 months, we have benefited from Nanxi's advice and guidance as a member of our Advisory Board, and we are pleased to now welcome her as a new member of the Board of Directors," said Joseph R. Shaposhnik, TCW Special Purpose Acquisition Corp. Chairman and CEO. "She is a highly successful technology entrepreneur and brings a unique perspective to the leaders of businesses and our impressive team of advisors and directors."

    TCW Special Purpose Acquisition Corp. intends to identify, merge with and take public a durable and predictable business well positioned to deliver superior revenue growth. Its management is associated with TCW's New America Premier business unit, which was established by Mr. Shaposhnik in 2015.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

    About TCW Special Purpose Acquisition Corp.

    TCW Special Purpose Acquisition Corp. (the "Company"), a Delaware corporation, is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with a private company. The Company is sponsored by The TCW Group, Inc., a leading global investment management firm with approximately $220 billion of assets under management. For more information please visit www.tcwspac.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005377/en/

    Get the next $ELAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN
    $PRTS
    $TSPQ
    $KIN

    CompanyDatePrice TargetRatingAnalyst
    Elanco Animal Health Incorporated
    $ELAN
    4/15/2026$30.00Buy
    Citigroup
    Elanco Animal Health Incorporated
    $ELAN
    1/22/2026Neutral → Overweight
    Piper Sandler
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2025$30.00Overweight
    Barclays
    Elanco Animal Health Incorporated
    $ELAN
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    Elanco Animal Health Incorporated
    $ELAN
    11/19/2025$25.00Hold → Buy
    Argus
    Elanco Animal Health Incorporated
    $ELAN
    10/7/2025$24.00Neutral → Overweight
    Analyst
    Elanco Animal Health Incorporated
    $ELAN
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    Elanco Animal Health Incorporated
    $ELAN
    6/26/2025Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Elanco Animal Health with a new price target

    Citigroup initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $30.00

    4/15/26 8:08:24 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Modi Rajeev A. bought $99,939 worth of shares (4,911 units at $20.35), increasing direct ownership by 3% to 160,812 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:39:20 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $99,843 worth of shares (4,971 units at $20.09) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:38:26 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm

    Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae INDIANAPOLIS , June 4, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today reaffirms its commitment to providing veterinarians, livestock produ

    6/4/26 6:26:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience

    INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry. According to Elanco's latest survey of 1,409 U.S. pet owners conducted May 29-31, even with rising costs across spending categories including higher gas prices, pet health and wellness remain an absolute priority for pet owners as a protected budget item.Stable Expectations for Pet Owner Spend:

    6/3/26 7:26:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market

    Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics todayBefrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmabStarts controlling itch within 24 hours and is given as an in-clinic injectionSelect Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomesMeet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their jo

    5/18/26 7:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    6/2/26 5:12:01 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    6/2/26 5:11:34 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    6/2/26 5:10:50 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    SEC Filings

    View All

    SEC Form S-8 filed by CarParts.com Inc.

    S-8 - CarParts.com, Inc. (0001378950) (Filer)

    6/1/26 5:21:17 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    SEC Form SD filed by Elanco Animal Health Incorporated

    SD - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:09:19 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:00:57 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Leadership Updates

    Live Leadership Updates

    View All

    National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer

    National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:AC

    4/24/26 9:00:00 AM ET
    $ACHC
    $ELAN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Financials

    Live finance-specific insights

    View All

    CarParts.com Reports First Quarter 2026 Results

    LONG BEACH, Calif., May 7, 2026 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle repair and maintenance needs, is reporting results for the first quarter ended April 4, 2026.  First Quarter 2026 Summary vs. Year-Ago Quarter Closed $8.0 million strategic investment.Net sales decreased 10% to $132.0 million.Gross profit of $42.9 million vs. $47.3 million, with gross margin of 32.5%.Net loss was ($1.9) million, or ($0.03) per share, compared to a net loss of ($15.3) million, or

    5/7/26 4:01:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Elanco Animal Health Reports First Quarter 2026 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y

    5/6/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CarParts.com Sets First Quarter 2026 Conference Call for Thursday, May 7, 2026

    LONG BEACH, Calif., April 16, 2026 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS) will hold a conference call on Thursday, May 7, 2026 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its financial results for the first quarter ended April 4, 2026. The results will be reported in a press release prior to the call. CarParts.com, Inc. CEO David Meniane and Interim CFO Mark DiSiena will host the conference call live via an audio webcast.The live webcast of the event can be accessed at www.carparts.com/investor/news-events. A replay of the webcast will be archived on

    4/16/26 4:01:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    11/12/24 1:35:28 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    11/4/24 10:24:21 AM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    9/10/24 12:09:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary